NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal ...
Abstract: Gastrointestinal (GI) diseases are most common worldwide and the death rate can be reduced by early detection. Endoscopy is widely regarded as the gold standard for diagnosing and managing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results